{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:40:25Z","timestamp":1792705225692,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-026-03581-6","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:11:36Z","timestamp":1792703496000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Understanding the High Pharmacokinetic Variability of 5-Aminosalicylic Acid Drug Products Using Compartmental, Semi-mechanistic, and Mechanistic Pharmacokinetic Models"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-1062-5860","authenticated-orcid":false,"given":"Sakshi","family":"Kunjir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1834-7750","authenticated-orcid":false,"given":"Sadhana","family":"Dhyagala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9362-8365","authenticated-orcid":false,"given":"Ayush","family":"Rohila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0603-1492","authenticated-orcid":false,"given":"Ankit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4148-171X","authenticated-orcid":false,"given":"Prakash Kumar","family":"Sirvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1435-6115","authenticated-orcid":false,"given":"Rajkumar","family":"Malayandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"3581_CR1","doi-asserted-by":"publisher","unstructured":"Wang R, Li Z, Liu S, Zhang D. Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019. BMJ Open. https:\/\/doi.org\/10.1136\/BMJOPEN-2022-065186.","DOI":"10.1136\/BMJOPEN-2022-065186"},{"key":"3581_CR2","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1053\/j.gastro.2018.12.009","volume":"156","author":"CW Ko","year":"2019","unstructured":"Ko CW, Singh S, Feuerstein JD, Falck-Ytter C, Falck-Ytter Y, Cross RK, et al. AGA Clinical Practice Guidelines on the management of mild-to-moderate ulcerative colitis. Gastroenterology. 2019;156:748\u201364. https:\/\/doi.org\/10.1053\/j.gastro.2018.12.009.","journal-title":"Gastroenterology"},{"key":"3581_CR3","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/GUTJNL-2019-318484","volume":"68","author":"CA Lamb","year":"2019","unstructured":"Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1-106. https:\/\/doi.org\/10.1136\/GUTJNL-2019-318484.","journal-title":"Gut"},{"key":"3581_CR4","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/456895","author":"C Perrotta","year":"2015","unstructured":"Perrotta C, Pellegrino P, Moroni E, De Palma C, Cervia D, Danelli P, et al. Five-Aminosalicylic Acid: an update for the reappraisal of an old drug. Gastroenterol Res Pract. 2015. https:\/\/doi.org\/10.1155\/2015\/456895.","journal-title":"Gastroenterol Res Pract"},{"key":"3581_CR5","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1023\/A:1018909527659","volume":"10","author":"DL French","year":"1993","unstructured":"French DL, Mauger JW. Evaluation of the physicochemical properties and dissolution characteristics of mesalamine: relevance to controlled intestinal drug delivery. Pharm Res. 1993;10:1285\u201390. https:\/\/doi.org\/10.1023\/A:1018909527659.","journal-title":"Pharm Res"},{"key":"3581_CR6","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1021\/MP100198Q","volume":"7","author":"HM Fadda","year":"2010","unstructured":"Fadda HM, Sousa T, Carlsson AS, Abrahamsson B, Williams JG, Kumar D, et al. Drug solubility in luminal fluids from different regions of the small and large intestine of humans. Mol Pharm. 2010;7:1527\u201332. https:\/\/doi.org\/10.1021\/MP100198Q.","journal-title":"Mol Pharm"},{"key":"3581_CR7","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jconrel.2022.04.024","volume":"346","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Wo SK, Leng W, Gao F, Yan X, Zuo Z. Population pharmacokinetics and IVIVC for mesalazine enteric-coated tablets. J Control Release. 2022;346:275\u201388. https:\/\/doi.org\/10.1016\/j.jconrel.2022.04.024.","journal-title":"J Control Release"},{"key":"3581_CR8","doi-asserted-by":"publisher","unstructured":"Sharma S, Kunjir SA, Pathare PR, Deoriya J, Sahoo A, Malayandi R. Effect of solid-state characteristics and buffers on the solubility and dissolution behaviors of mesalamine. J Therm Anal Calorim 2025 15012. Springer; 2025;150:9153\u201369. https:\/\/doi.org\/10.1007\/S10973-025-14231-7.","DOI":"10.1007\/S10973-025-14231-7"},{"key":"3581_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/BF01312463","author":"U Klotz","year":"1987","unstructured":"Klotz U, Maier KE. Pharmacology and pharmacokinetics of 5-aminosalicylic acid. Dig Dis Sci. 1987. https:\/\/doi.org\/10.1007\/BF01312463.","journal-title":"Dig Dis Sci"},{"key":"3581_CR10","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.bbrc.2020.01.139","volume":"524","author":"T Yuri","year":"2020","unstructured":"Yuri T, Kono Y, Fujita T. Transport characteristics of 5-aminosalicylic acid into colonic epithelium: involvement of sodium-coupled monocarboxylate transporter SMCT1-mediated transport system. Biochem Biophys Res Commun. 2020;524:561\u20136. https:\/\/doi.org\/10.1016\/j.bbrc.2020.01.139.","journal-title":"Biochem Biophys Res Commun"},{"key":"3581_CR11","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1124\/DMD.110.034991","volume":"39","author":"J K\u00f6nig","year":"2011","unstructured":"K\u00f6nig J, Glaeser H, Keiser M, Mandery K, Klotz U, Fromm MF. Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake. Drug Metab Dispos. 2011;39:1097\u2013102. https:\/\/doi.org\/10.1124\/DMD.110.034991.","journal-title":"Drug Metab Dispos"},{"key":"3581_CR12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.4149\/GPB_2013034","volume":"32","author":"L Smetanov\u00e1","year":"2013","unstructured":"Smetanov\u00e1 L, \u0160t\u011btinov\u00e1 V, Kholov\u00e1 D, Kune\u0161 M, Nobilis M, Svoboda Z, et al. Transintestinal transport mechanisms of 5-aminosalicylic acid (in situ rat intestine perfusion, Caco-2 cells) and Biopharmaceutics Classification System. Gen Physiol Biophys. 2013;32:361\u20139. https:\/\/doi.org\/10.4149\/GPB_2013034.","journal-title":"Gen Physiol Biophys"},{"key":"3581_CR13","doi-asserted-by":"publisher","first-page":"5665","DOI":"10.3748\/WJG.V19.I34.5665","volume":"19","author":"R D\u2019Inc\u00e0","year":"2013","unstructured":"D\u2019Inc\u00e0 R, Paccagnella M, Cardin R, Pathak S, Baldo V, Giron MC, et al. 5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis. World J Gastroenterol. 2013;19:5665\u201370. https:\/\/doi.org\/10.3748\/WJG.V19.I34.5665.","journal-title":"World J Gastroenterol"},{"key":"3581_CR14","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/J.ADDR.2004.08.008","volume":"57","author":"AI Qureshi","year":"2005","unstructured":"Qureshi AI, Cohen RD. Mesalamine delivery systems: do they really make much difference? Adv Drug Deliv Rev. 2005;57:281\u2013302. https:\/\/doi.org\/10.1016\/J.ADDR.2004.08.008.","journal-title":"Adv Drug Deliv Rev"},{"key":"3581_CR15","doi-asserted-by":"publisher","unstructured":"Salazar-Gonz\u00e1lez RA, Doll MA, Hein DW. Human arylamine N-acetyltransferase 2 genotype-dependent protein expression in cryopreserved human hepatocytes. Sci Reports 2020 101. Nature Publishing Group; 2020;10:7566-. https:\/\/doi.org\/10.1038\/s41598-020-64508-0.","DOI":"10.1038\/s41598-020-64508-0"},{"key":"3581_CR16","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/BPH.12182","volume":"169","author":"X Zhou","year":"2013","unstructured":"Zhou X, Ma Z, Dong D, Wu B. Arylamine N-acetyltransferases: a structural perspective. Br J Pharmacol. 2013;169:748\u201360. https:\/\/doi.org\/10.1111\/BPH.12182.","journal-title":"Br J Pharmacol"},{"key":"3581_CR17","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1136\/GUT.42.3.402","volume":"42","author":"D Hickman","year":"1998","unstructured":"Hickman D, Pope J, Patil SD, Fakis G, Smelt V, Stanley LA, et al. Expression of arylamine N -acetyltransferase in human intestine. Gut. 1998;42:402\u20139. https:\/\/doi.org\/10.1136\/GUT.42.3.402.","journal-title":"Gut"},{"key":"3581_CR18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1055\/S-2007-963673","volume":"46","author":"M Hausmann","year":"2008","unstructured":"Hausmann M, Paul G, Menzel K, Brunner-Ploss R, Falk W, Sch\u00f6lmerich J, et al. NAT1 genotypes do not predict response to mesalamine in patients with ulcerative colitis. Z Gastroenterol. 2008;46:259\u201365. https:\/\/doi.org\/10.1055\/S-2007-963673.","journal-title":"Z Gastroenterol"},{"key":"3581_CR19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/0016-5085(89)91412-1","volume":"97","author":"H Allgayer","year":"1989","unstructured":"Allgayer H, Ahnfelt NO, Kruis W, Klotz U, Frank-Holmberg K, S\u00f6derberg HNA, et al. Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease. Gastroenterology. 1989;97:38\u201341. https:\/\/doi.org\/10.1016\/0016-5085(89)91412-1.","journal-title":"Gastroenterology"},{"key":"3581_CR20","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/J.DLD.2024.04.012","volume":"56","author":"F D\u2019Amico","year":"2024","unstructured":"D\u2019Amico F, Lusetti F, Peyrin-Biroulet L, Danese S. MMX mesalamine in ulcerative colitis: major advantages towards classical mesalamine formulations. Dig Liver Dis. 2024;56:1425\u201332. https:\/\/doi.org\/10.1016\/J.DLD.2024.04.012.","journal-title":"Dig Liver Dis"},{"key":"3581_CR21","doi-asserted-by":"publisher","first-page":"5283","DOI":"10.1021\/CG501084A","volume":"14","author":"SR Modi","year":"2014","unstructured":"Modi SR, Dantuluri AKR, Perumalla SR, Sun CC, Bansal AK. Effect of crystal habit on intrinsic dissolution behavior of celecoxib due to differential wettability. Cryst Growth Des. 2014;14:5283\u201392. https:\/\/doi.org\/10.1021\/CG501084A.","journal-title":"Cryst Growth Des"},{"key":"3581_CR22","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1016\/J.XPHS.2024.02.001","volume":"113","author":"SM Shah","year":"2024","unstructured":"Shah SM, Chakraborty S, Dubey G, Yewale S, Sathe RY, Ramaswamy L, et al. Effect of differential surface anisotropy on dissolution behavior of fenofibrate crystal habits: comparative study using USP type 2 and type 4 dissolution apparatuses. J Pharm Sci. 2024;113:1844\u201353. https:\/\/doi.org\/10.1016\/J.XPHS.2024.02.001.","journal-title":"J Pharm Sci"},{"key":"3581_CR23","unstructured":"He J, Bhatti M, Lutter L. Studies selected the investigation of variability of the pharmacokinetics of mesalamine from various mesalamine formulations in randomized clinical trials absorption rate (ka) for 5-ASA and N-acetyl-5-ASA. www.biopharmaservices.ca. Accessed 13 Jul 2026."},{"key":"3581_CR24","doi-asserted-by":"publisher","first-page":"4181","DOI":"10.1021\/ACS.MOLPHARMACEUT.6B01129","volume":"14","author":"D Georgaka","year":"2017","unstructured":"Georgaka D, Butler J, Kesisoglou F, Reppas C, Vertzoni M. Evaluation of dissolution in the lower intestine and its impact on the absorption process of high dose low solubility drugs. Mol Pharm. 2017;14:4181\u201391. https:\/\/doi.org\/10.1021\/ACS.MOLPHARMACEUT.6B01129.","journal-title":"Mol Pharm"},{"key":"3581_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/PSP4.70246","author":"L Cheng","year":"2026","unstructured":"Cheng L, Cai J, Auster A, Cho S, Keir M, Rhee H, et al. Translational modeling of gut microbiome-mediated drug metabolism: a case example of sulfasalazine. CPT Pharmacomet Syst Pharmacol. 2026. https:\/\/doi.org\/10.1002\/PSP4.70246.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"3581_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/J.IJPHARM.2025.125547","author":"H Jadhav","year":"2025","unstructured":"Jadhav H, Camp AV, Tannergren C, Lemmens G, Brouwers J, Vanuytsel T, et al. Challenges in predicting colonic luminal and tissue concentrations of mesalamine and acetyl mesalamine using physiologically based biopharmaceutics modeling. Int J Pharm. 2025. https:\/\/doi.org\/10.1016\/J.IJPHARM.2025.125547.","journal-title":"Int J Pharm"},{"key":"3581_CR27","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/BDD.2315","volume":"43","author":"D Mukherjee","year":"2022","unstructured":"Mukherjee D, Chiney MS, Shao X, Ju TR, Shebley M, Marroum P. Physiologically based pharmacokinetic modeling and simulations to inform dissolution specifications and clinical relevance of release rates on elagolix exposure. Biopharm Drug Dispos. 2022;43:98\u2013107. https:\/\/doi.org\/10.1002\/BDD.2315.","journal-title":"Biopharm Drug Dispos"},{"key":"3581_CR28","doi-asserted-by":"publisher","unstructured":"Pawar G, Wu F, Zhao L, Fang L, Burckart GJ, Feng K, et al. Integration of biorelevant pediatric dissolution methodology into PBPK modeling to predict in vivo performance and bioequivalence of generic drugs in pediatric populations: a carbamazepine case study. AAPS J. 2023; 25:67-. https:\/\/doi.org\/10.1208\/S12248-023-00826-1.","DOI":"10.1208\/S12248-023-00826-1"},{"key":"3581_CR29","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/BF01296618","volume":"36","author":"S Bondesen","year":"1991","unstructured":"Bondesen S, Hegnh\u00f8j J, Larsen F, Hansen SH, Hansen CP, Rasmussen SN. Pharmacokinetics of 5-aminosalicylic acid in man following administration of intravenous bolus and per os slow-release formulation. Dig Dis Sci. 1991;36:1735\u201340. https:\/\/doi.org\/10.1007\/BF01296618.","journal-title":"Dig Dis Sci"},{"key":"3581_CR30","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/GUT.28.2.196","volume":"28","author":"B Myers","year":"1987","unstructured":"Myers B, Evans DNW, Rhodes J, Evans BK, Hughes BR, Lee MG, et al. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut. 1987;28:196\u2013200. https:\/\/doi.org\/10.1136\/GUT.28.2.196.","journal-title":"Gut"},{"key":"3581_CR31","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1021\/ACS.MOLPHARMACEUT.6B00641","volume":"14","author":"A Yu","year":"2017","unstructured":"Yu A, Baker JR, Fioritto AF, Wang Y, Luo R, Li S, et al. Measurement of in vivo gastrointestinal release and dissolution of three locally acting mesalamine formulations in regions of the human gastrointestinal tract. Mol Pharm. 2017;14:345\u201358. https:\/\/doi.org\/10.1021\/ACS.MOLPHARMACEUT.6B00641.","journal-title":"Mol Pharm"},{"key":"3581_CR32","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/BF00198311","volume":"48","author":"DK Yu","year":"1995","unstructured":"Yu DK, Morrill B, Eichmeier LS, Giesing DH, Weir SJ, Lanman RC, et al. Pharmacokinetics of 5-aminosalicylic acid from controlled-release capsules in man. Eur J Clin Pharmacol. 1995;48:273\u20137. https:\/\/doi.org\/10.1007\/BF00198311.","journal-title":"Eur J Clin Pharmacol"},{"key":"3581_CR33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/CLPT.1990.113","volume":"48","author":"DK Yu","year":"1990","unstructured":"Yu DK, Elvin AT, Morrill B, Eichmeier LS, Lanman RC, Lanman MB, et al. Effect of food coadministration on 5-aminosalicylic acid oral suspension bioavailability. Clin Pharmacol Ther. 1990;48:26\u201333. https:\/\/doi.org\/10.1038\/CLPT.1990.113.","journal-title":"Clin Pharmacol Ther"},{"key":"3581_CR34","unstructured":"Clinical Pharmacology and, Biopharmaceutics Review(S). Center for Drug Evaluation and Research. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2007\/022000s000_ClinPharmR.pdf. Accessed 14 Jul 2026."},{"key":"3581_CR35","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1111\/BCP.14479","volume":"87","author":"N Vande Casteele","year":"2021","unstructured":"Vande Casteele N, Jakate A, McNamee B, Sandborn WJ. Similar pharmacokinetics of three dosing regimens comprising two oral delayed-release mesalamine formulations in healthy adult volunteers: randomised, open-label, parallel-group study. Br J Clin Pharmacol. 2021;87:1141\u20139. https:\/\/doi.org\/10.1111\/BCP.14479.","journal-title":"Br J Clin Pharmacol"},{"key":"3581_CR36","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1177\/0091270006296522","volume":"47","author":"P Gandia","year":"2007","unstructured":"Gandia P, Idier I, Houin G. Is once-daily mesalazine equivalent to the currently used twice-daily regimen? A study performed in 30 healthy volunteers. J Clin Pharmacol. 2007;47:334\u201342. https:\/\/doi.org\/10.1177\/0091270006296522.","journal-title":"J Clin Pharmacol"},{"key":"3581_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/J.IJPHARM.2022.121701","volume":"619","author":"A Van Camp","year":"2022","unstructured":"Van Camp A, Vanuytsel T, Brouwers J, Augustijns P. The effect of esomeprazole on the upper GI tract release and systemic absorption of mesalazine from colon targeted formulations. Int J Pharm. 2022;619:121701. https:\/\/doi.org\/10.1016\/J.IJPHARM.2022.121701.","journal-title":"Int J Pharm"},{"key":"3581_CR38","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/J.1365-2036.1994.TB00290.X","volume":"8","author":"LA Christensen","year":"1994","unstructured":"Christensen LA, Fallingborg J, Jacobsen BA, Abildgaard K, Rasmussen HH, Hansen SH, et al. Comparative bioavailability of 5-aminosalicylic acid from a controlled release preparation and an azo-bond preparation. Aliment Pharmacol Ther. 1994;8:289\u201394. https:\/\/doi.org\/10.1111\/J.1365-2036.1994.TB00290.X.","journal-title":"Aliment Pharmacol Ther"},{"key":"3581_CR39","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3109\/00365528809093858","volume":"23","author":"MCM Rijk","year":"1988","unstructured":"Rijk MCM, Schaik AV, Tongeren JHMV. Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivering compounds. Scand J Gastroenterol. 1988;23:107\u201312. https:\/\/doi.org\/10.3109\/00365528809093858.","journal-title":"Scand J Gastroenterol"},{"key":"3581_CR40","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2165\/00044011-200020010-00005","volume":"20","author":"TB Vree","year":"2012","unstructured":"Vree TB, Dammers E, Exler PS, S\u00f6rgel F, Maes RAA. Saturable active tubular reabsorption in the renal clearance of mesalazine in human volunteers. Clin Drug Investig. 2012;20:35\u201342. https:\/\/doi.org\/10.2165\/00044011-200020010-00005.","journal-title":"Clin Drug Investig"},{"key":"3581_CR41","doi-asserted-by":"publisher","DOI":"10.1208\/S12249-024-02990-9","author":"S Kollipara","year":"2024","unstructured":"Kollipara S, Prabhat PK, Saha P, Gupta S, Naidu VR, Ahmed T. Physiologically based biopharmaceutics modeling coupled with biopredictive dissolution in development of bioequivalent formulation for mesalamine enteric coated tablet: a tough nut to crack. AAPS PharmSciTech. 2024. https:\/\/doi.org\/10.1208\/S12249-024-02990-9.","journal-title":"AAPS PharmSciTech"},{"key":"3581_CR42","doi-asserted-by":"publisher","unstructured":"Dash AK, Brittain HG. Mesalamine. Anal profiles drug subst excipients. Elsevier Inc.; 1998;25:209\u201342. https:\/\/doi.org\/10.1016\/S0099-5428(08)60756-X.","DOI":"10.1016\/S0099-5428(08)60756-X"},{"key":"3581_CR43","doi-asserted-by":"publisher","DOI":"10.1208\/S12249-024-03006-2","author":"F Bi","year":"2024","unstructured":"Bi F, Yuan T, Zhang B, Li J, Lin Y, Yang J. Establishment of biopredictive dissolution and bioequivalence safe space using the physiologically based biopharmaceutics modeling for tacrolimus extended-release capsules. AAPS PharmSciTech. 2024. https:\/\/doi.org\/10.1208\/S12249-024-03006-2.","journal-title":"AAPS PharmSciTech"},{"key":"3581_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/J.CMPB.2020.105322","author":"J Reig-Lopez","year":"2020","unstructured":"Reig-Lopez J, Merino-Sanjuan M, Mangas-Sanjuan V, Prado-Velasco M. A multilevel object-oriented modelling methodology for physiologically-based pharmacokinetics (PBPK): evaluation with a semi-mechanistic pharmacokinetic model. Comput Methods Programs Biomed. 2020. https:\/\/doi.org\/10.1016\/J.CMPB.2020.105322.","journal-title":"Comput Methods Programs Biomed"},{"key":"3581_CR45","doi-asserted-by":"publisher","first-page":"14601","DOI":"10.1021\/ACS.IECR.5C01387","volume":"64","author":"A Khambhawala","year":"2025","unstructured":"Khambhawala A, Lee CH, Kwon JsI. Accelerating drug discovery with hybrid physiologically based pharmacokinetic (PBPK) models: a transformer-based approach for pharmacokinetic predictions. Ind Eng Chem Res. 2025;64:14601\u201315. https:\/\/doi.org\/10.1021\/ACS.IECR.5C01387.","journal-title":"Ind Eng Chem Res"},{"key":"3581_CR46","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1021\/MP200275J","volume":"9","author":"BS Abuasal","year":"2012","unstructured":"Abuasal BS, Bolger MB, Walker DK, Kaddoumi A. In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate. Mol Pharm. 2012;9:492\u2013504. https:\/\/doi.org\/10.1021\/MP200275J.","journal-title":"Mol Pharm"},{"key":"3581_CR47","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1208\/S12248-015-9758-0","volume":"17","author":"A Olivares-Morales","year":"2015","unstructured":"Olivares-Morales A, Lennern\u00e4s H, Aarons L, Rostami-Hodjegan A. Translating human effective jejunal intestinal permeability to surface-dependent intrinsic permeability: a pragmatic method for a more mechanistic prediction of regional oral drug absorption. AAPS J. 2015;17:1177\u201392. https:\/\/doi.org\/10.1208\/S12248-015-9758-0.","journal-title":"AAPS J"},{"key":"3581_CR48","doi-asserted-by":"publisher","DOI":"10.1208\/S12249-026-03434-2","author":"A Kumar","year":"2026","unstructured":"Kumar A, Kunjir S, Sirvi PK, Rohila A, Dhyagala S, Malayandi R. Understanding the influence of molarity, buffer capacity, and pH on product-specific guidance dissolution method for developing a discriminatory dissolution method for the development of mesalamine products. AAPS PharmSciTech. 2026. https:\/\/doi.org\/10.1208\/S12249-026-03434-2.","journal-title":"AAPS PharmSciTech"},{"issue":"5","key":"3581_CR49","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1208\/S12249-023-02577-W","volume":"24","author":"SS Kesharwani","year":"2023","unstructured":"Kesharwani SS, Ibrahim F. A combined in-vitro and GastroPlus\u00ae modeling to study the effect of intestinal precipitation on cinnarizine plasma profile in a fasted state. AAPS PharmSciTech. 2023;24:121. https:\/\/doi.org\/10.1208\/S12249-023-02577-W.","journal-title":"AAPS PharmSciTech"},{"key":"3581_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/PH17070876","author":"S Kollipara","year":"2024","unstructured":"Kollipara S, Martins FS, Jereb R, Krajcar D, Ahmed T. Advancing virtual bioequivalence for orally administered drug products: methodology, real-world applications and future outlook. Pharmaceuticals (Basel). 2024. https:\/\/doi.org\/10.3390\/PH17070876.","journal-title":"Pharmaceuticals (Basel)"},{"key":"3581_CR51","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1021\/ACS.MOLPHARMACEUT.5B00602","volume":"12","author":"M Sugihara","year":"2026","unstructured":"Sugihara M, Takeuchi S, Sugita M, Higaki K, Kataoka M, Yamashita S. Analysis of intra- and intersubject variability inoral drug absorption in human bioequivalence studies of 113 genericproducts. Mol Pharm. 2026;12:4405\u201313. https:\/\/doi.org\/10.1021\/ACS.MOLPHARMACEUT.5B00602.","journal-title":"Mol Pharm"},{"key":"3581_CR52","doi-asserted-by":"publisher","DOI":"10.1208\/S12248-021-00672-Z","author":"M Bego","year":"2022","unstructured":"Bego M, Patel N, Cristofoletti R, Rostami-Hodjegan A. Proof of concept in assignment of within-subject variability during virtual bioequivalence studies: propagation of intra-subject variation in gastrointestinal physiology using physiologically based pharmacokinetic modeling. AAPS J. 2022. https:\/\/doi.org\/10.1208\/S12248-021-00672-Z.","journal-title":"AAPS J"},{"key":"3581_CR53","doi-asserted-by":"publisher","DOI":"10.1208\/S12248-024-00956-0","author":"R Yang","year":"2024","unstructured":"Yang R, Lin Y, Chen K, Huang J, Yang S, Yao A, et al. Establishing virtual bioequivalence and clinically relevant specifications for omeprazole enteric-coated capsules by incorporating dissolution data in PBPK modeling. AAPS J. 2024. https:\/\/doi.org\/10.1208\/S12248-024-00956-0.","journal-title":"AAPS J"},{"key":"3581_CR54","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ijpharm.2015.02.051","volume":"484","author":"A Goyanes","year":"2015","unstructured":"Goyanes A, Hatton GB, Merchant HA, Basit AW. Gastrointestinal release behaviour of modified-release drug products: dynamic dissolution testing of mesalazine formulations. Int J Pharm. 2015;484:103\u20138. https:\/\/doi.org\/10.1016\/j.ijpharm.2015.02.051.","journal-title":"Int J Pharm"},{"key":"3581_CR55","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1021\/ACS.MOLPHARMACEUT.0C00614","volume":"17","author":"N Salehi","year":"2020","unstructured":"Salehi N, Al-Gousous J, Mudie DM, Amidon GL, Ziff RM, Amidon GE. Hierarchical mass transfer analysis of drug particle dissolution, highlighting the hydrodynamics, pH, particle size, and buffer effects for the dissolution of ionizable and nonionizable drugs in a compendial dissolution vessel. Mol Pharm. 2020;17:3870\u201384. https:\/\/doi.org\/10.1021\/ACS.MOLPHARMACEUT.0C00614.","journal-title":"Mol Pharm"},{"key":"3581_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/PHARMACEUTICS14020291","author":"MA Garc\u00eda","year":"2022","unstructured":"Garc\u00eda MA, Varum F, Al-Gousous J, Hofmann M, Page S, Langguth P. In vitro methodologies for evaluating colon-targeted pharmaceutical products and industry perspectives for their applications. Pharmaceutics (Basel). 2022. https:\/\/doi.org\/10.3390\/PHARMACEUTICS14020291.","journal-title":"Pharmaceutics (Basel)"},{"key":"3581_CR57","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/S12325-015-0206-4","volume":"32","author":"A Abinusawa","year":"2015","unstructured":"Abinusawa A, Tenjarla S. Release of 5-aminosalicylic acid (5-ASA) from mesalamine formulations at various pH levels. Adv Ther. 2015;32:477\u201384. https:\/\/doi.org\/10.1007\/S12325-015-0206-4.","journal-title":"Adv Ther"},{"key":"3581_CR58","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/J.EJPS.2012.06.013","volume":"47","author":"AT Heikkinen","year":"2012","unstructured":"Heikkinen AT, Baneyx G, Caruso A, Parrott N. Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates - an evaluation and case study using GastroPlus. Eur J Pharm Sci. 2012;47:375\u201386. https:\/\/doi.org\/10.1016\/J.EJPS.2012.06.013.","journal-title":"Eur J Pharm Sci"},{"key":"3581_CR59","doi-asserted-by":"publisher","first-page":"18","DOI":"10.14227\/DT220315P18","volume":"22","author":"M Bogataj","year":"2015","unstructured":"Bogataj M, Cof G, Mrhar A. Development of a glass-bead device for dissolution testing. Dissolut Technol. 2015;22:18\u201324. https:\/\/doi.org\/10.14227\/DT220315P18.","journal-title":"Dissolut Technol"},{"key":"3581_CR60","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.3390\/PHARMACEUTICS16121567\/S1","volume":"16","author":"Y Maeda","year":"2024","unstructured":"Maeda Y, Goto Y, Ohnishi F, Koga S, Kawano S, Hieda Y, et al. 5-Aminosalicylic acid distribution into the intestinal membrane along the gastrointestinal tract after oral administration in rats. Pharmaceutics. 2024;16:1567. https:\/\/doi.org\/10.3390\/PHARMACEUTICS16121567\/S1.","journal-title":"Pharmaceutics"},{"key":"3581_CR61","unstructured":"Carsten Hoeg-Moller. Granules for pharmaceutical preparations, methods and apparatus for ther production. US Pat. 2014; US 8,765,185 B2. https:\/\/patents.google.com\/patent\/US8765185B2\/en?oq=8765185+"},{"key":"3581_CR62","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1046\/J.1365-2036.2000.00696.X","volume":"14","author":"IR Wilding","year":"2000","unstructured":"Wilding IR, Kenyon CJ, Hooper G. Gastrointestinal spread of oral prolonged-release mesalazine microgranules (Pentasa) dosed as either tablets or sachet. Aliment Pharmacol Ther. 2000;14:163\u20139. https:\/\/doi.org\/10.1046\/J.1365-2036.2000.00696.X","journal-title":"Aliment Pharmacol Ther"},{"key":"3581_CR63","doi-asserted-by":"publisher","unstructured":"Abadi BGJ, Esfahani K, Manjili HK. Evaluation of NAT1 gene expression and methylation in the blood of people with breast cancer. Int J Health Sci. 2022;12218\u201336. https:\/\/doi.org\/10.53730\/IJHS.V6NS2.8162.","DOI":"10.53730\/IJHS.V6NS2.8162"},{"key":"3581_CR64","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/S12199-017-0681-0","volume":"22","author":"M Koda","year":"2017","unstructured":"Koda M, Iwasaki M, Yamano Y, Lu X, Katoh T. Association between NAT2, CYP1A1, and CYP1A2 genotypes, heterocyclic aromatic amines, and prostate cancer risk: a case control study in Japan. Environ Health Prev Med. 2017;22:72. https:\/\/doi.org\/10.1186\/S12199-017-0681-0.","journal-title":"Environ Health Prev Med"},{"key":"3581_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/J.GENREP.2021.101343","author":"S Saleem","year":"2021","unstructured":"Saleem S, Tahir IM, Iqbal T, Jamil A, Mehboob H, Akram M, et al. Genetic polymorphism of NAT1 in local Pakistani population. Gene Rep. 2021. https:\/\/doi.org\/10.1016\/J.GENREP.2021.101343.","journal-title":"Gene Rep"},{"key":"3581_CR66","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1097\/01.FPC.0000215071.59836.29","volume":"16","author":"LM Morton","year":"2006","unstructured":"Morton LM, Schenk M, Hein DW, Davis S, Zahm SH, Cozen W, et al. Genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2) and risk of non-Hodgkin lymphoma. Pharmacogenet Genomics. 2006;16:537. https:\/\/doi.org\/10.1097\/01.FPC.0000215071.59836.29.","journal-title":"Pharmacogenet Genomics"},{"key":"3581_CR67","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1080\/10937400903158383","volume":"12","author":"K Walker","year":"2009","unstructured":"Walker K, Ginsberg G, Hattis D, Johns DO, Guyton KZ, Sonawane B. Genetic polymorphism in N-Acetyltransferase (NAT): population distribution of NAT1 and NAT2 activity. J Toxicol Environ Health B Crit Rev. 2009;12:440\u201372. https:\/\/doi.org\/10.1080\/10937400903158383.","journal-title":"J Toxicol Environ Health B Crit Rev"},{"key":"3581_CR68","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2147\/CEG.S35691","volume":"7","author":"SK B\u00f6hm","year":"2014","unstructured":"B\u00f6hm SK, Kruis W. Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis. Clin Exp Gastroenterol. 2014;7:369. https:\/\/doi.org\/10.2147\/CEG.S35691.","journal-title":"Clin Exp Gastroenterol"},{"key":"3581_CR69","unstructured":"He J, Bhatti M, Lutter L. Studies Selected The investigation of variability of the pharmacokinetics of mesalamine from various mesalamine formulations in randomized clinical trials Absorption Rate (ka) for 5-ASA and N-acetyl-5-ASA; www.biopharmaservices.ca. Accessed 14 Jul 2026."}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03581-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03581-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03581-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:11:38Z","timestamp":1792703498000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03581-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":69,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["3581"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03581-6","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"21 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"331"}}